News

Vertex Pharmaceuticals today announced that Health Canada has granted Marketing Authorization for PrALYFTREKTM (vanzacaftor/tezacaftor/deutivacaftor), a new triple combination therapy for patients ...
Vertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...
NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...
Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...
Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...
Vertex Pharmaceuticals Incorporated today announced that the U.S. Food and Drug Administration has approved ALYFTREK, a once-daily next-in-class triple combination cystic fibrosis transmembrane ...
Vertex Pharmaceuticals has announced a broad reimbursement agreement with NHS England for ALYFTREK ...
Trikafta goes for $346,043 a year — before insurance reimbursement and rebates — while Alyftrek will cost $370,269, Abrahams said. Alyftrek is a once-daily pill.
Alyftrek (vanza triple), Vertex’s new once-a-day oral triple combination medicine for treating people with CF aged six years and older, has the potential to provide better patient benefit than ...
ALYFTREK is not recommended in patients with moderate hepatic impairment (Child-Pugh Class B) and should only be considered when there is a clear medical need, and benefit outweighs risk.